Australia markets closed

Travere Therapeutics, Inc. (TVTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.76-0.18 (-2.27%)
As of 02:30PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 604.46M
Enterprise value 567.44M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.90
Price/book (mrq)8.16
Enterprise value/revenue 3.64
Enterprise value/EBITDA -5.67

Trading information

Stock price history

Beta (5Y monthly) 0.78
52-week change 3-48.84%
S&P500 52-week change 325.87%
52-week high 317.57
52-week low 35.12
50-day moving average 36.88
200-day moving average 37.60

Share statistics

Avg vol (3-month) 31.26M
Avg vol (10-day) 31.59M
Shares outstanding 576.13M
Implied shares outstanding 676.13M
Float 856.1M
% held by insiders 10.73%
% held by institutions 1118.98%
Shares short (14 June 2024) 413.41M
Short ratio (14 June 2024) 413.87
Short % of float (14 June 2024) 419.83%
Short % of shares outstanding (14 June 2024) 417.62%
Shares short (prior month 15 May 2024) 413.44M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -103.47%
Operating margin (ttm)-335.91%

Management effectiveness

Return on assets (ttm)-35.53%
Return on equity (ttm)-315.89%

Income statement

Revenue (ttm)155.72M
Revenue per share (ttm)2.04
Quarterly revenue growth (yoy)33.90%
Gross profit (ttm)N/A
EBITDA -376.56M
Net income avi to common (ttm)-415.73M
Diluted EPS (ttm)-5.41
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)441.04M
Total cash per share (mrq)5.79
Total debt (mrq)404.02M
Total debt/equity (mrq)545.44%
Current ratio (mrq)2.78
Book value per share (mrq)0.97

Cash flow statement

Operating cash flow (ttm)-317.91M
Levered free cash flow (ttm)-159.79M